This newsletter presents you the following key sessions:
1. Podcast with Prof. Natasha Leighl about the use of amivantamab in patients with advanced non-small cell
lung cancer and MET Exon 14 skipping mutations
2. Transforming patient care with a revised classification for lung adenocarcinomas
3. Iruplinalkib improves progression-free survival versus crizotinib in locally advanced or metastatic
ALK-positive NSCLC
4. IMpower151 fails to meet its primary endpoint of investigator-assessed progression-free survival
5. Addition of nivolumab to stereotactic ablative radiotherapy in early-stage non-small cell lung cancer